Grape-Seed Proanthocyanidin Extract Reverts Obesity-Related Metabolic Derangements in Aged Female Rats. 2021

Marta Sierra-Cruz, and Alba Miguéns-Gómez, and Carme Grau-Bové, and Esther Rodríguez-Gallego, and Mayte Blay, and Montserrat Pinent, and Anna Ardévol, and Ximena Terra, and Raúl Beltrán-Debón
MoBioFood Research Group, Department of Biochemistry and Biotechnology, Universitat Rovira i Virgili, 43007 Tarragona, Spain.

Obesity and ageing are current issues of global concern. Adaptive homeostasis is compromised in the elderly, who are more likely to suffer age-related health issues, such as obesity, metabolic syndrome, and cardiovascular disease. The current worldwide prevalence of obesity and higher life expectancy call for new strategies for treating metabolic disorders. Grape-seed proanthocyanidin extract (GSPE) is reported to be effective in ameliorating these pathologies, especially in young animal models. In this study, we aimed to test the effectiveness of GSPE in modulating obesity-related pathologies in aged rats fed an obesogenic diet. To do so, 21-month-old rats were fed a high-fat/high-sucrose diet (cafeteria diet) for 11 weeks. Two time points for GSPE administration (500 mg/kg body weight), i.e., a 10-day preventive GSPE treatment prior to cafeteria diet intervention and a simultaneous GSPE treatment with the cafeteria diet, were assayed. Body weight, metabolic parameters, liver steatosis, and systemic inflammation were analysed. GSPE administered simultaneously with the cafeteria diet was effective in reducing body weight, total adiposity, and liver steatosis. However, the preventive treatment was effective in reducing only mesenteric adiposity in these obese, aged rats. Our results confirm that the simultaneous administration of GSPE improves metabolic disruptions caused by the cafeteria diet also in aged rats.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005234 Fatty Liver Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS. Liver Steatosis,Steatohepatitis,Steatosis of Liver,Visceral Steatosis,Liver Steatoses,Liver, Fatty,Steatohepatitides,Steatoses, Liver,Steatoses, Visceral,Steatosis, Liver,Steatosis, Visceral,Visceral Steatoses
D005260 Female Females
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015431 Weight Loss Decrease in existing BODY WEIGHT. Weight Reduction,Loss, Weight,Losses, Weight,Reduction, Weight,Reductions, Weight,Weight Losses,Weight Reductions
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats

Related Publications

Marta Sierra-Cruz, and Alba Miguéns-Gómez, and Carme Grau-Bové, and Esther Rodríguez-Gallego, and Mayte Blay, and Montserrat Pinent, and Anna Ardévol, and Ximena Terra, and Raúl Beltrán-Debón
January 2020, Obesity facts,
Marta Sierra-Cruz, and Alba Miguéns-Gómez, and Carme Grau-Bové, and Esther Rodríguez-Gallego, and Mayte Blay, and Montserrat Pinent, and Anna Ardévol, and Ximena Terra, and Raúl Beltrán-Debón
March 2014, Food & function,
Marta Sierra-Cruz, and Alba Miguéns-Gómez, and Carme Grau-Bové, and Esther Rodríguez-Gallego, and Mayte Blay, and Montserrat Pinent, and Anna Ardévol, and Ximena Terra, and Raúl Beltrán-Debón
June 2012, The American journal of the medical sciences,
Marta Sierra-Cruz, and Alba Miguéns-Gómez, and Carme Grau-Bové, and Esther Rodríguez-Gallego, and Mayte Blay, and Montserrat Pinent, and Anna Ardévol, and Ximena Terra, and Raúl Beltrán-Debón
June 2003, Pharmacological research,
Marta Sierra-Cruz, and Alba Miguéns-Gómez, and Carme Grau-Bové, and Esther Rodríguez-Gallego, and Mayte Blay, and Montserrat Pinent, and Anna Ardévol, and Ximena Terra, and Raúl Beltrán-Debón
April 2014, Molecular nutrition & food research,
Marta Sierra-Cruz, and Alba Miguéns-Gómez, and Carme Grau-Bové, and Esther Rodríguez-Gallego, and Mayte Blay, and Montserrat Pinent, and Anna Ardévol, and Ximena Terra, and Raúl Beltrán-Debón
April 2019, RSC advances,
Marta Sierra-Cruz, and Alba Miguéns-Gómez, and Carme Grau-Bové, and Esther Rodríguez-Gallego, and Mayte Blay, and Montserrat Pinent, and Anna Ardévol, and Ximena Terra, and Raúl Beltrán-Debón
November 2011, Experimental gerontology,
Marta Sierra-Cruz, and Alba Miguéns-Gómez, and Carme Grau-Bové, and Esther Rodríguez-Gallego, and Mayte Blay, and Montserrat Pinent, and Anna Ardévol, and Ximena Terra, and Raúl Beltrán-Debón
October 2011, Experimental & molecular medicine,
Marta Sierra-Cruz, and Alba Miguéns-Gómez, and Carme Grau-Bové, and Esther Rodríguez-Gallego, and Mayte Blay, and Montserrat Pinent, and Anna Ardévol, and Ximena Terra, and Raúl Beltrán-Debón
June 2009, Immunology letters,
Marta Sierra-Cruz, and Alba Miguéns-Gómez, and Carme Grau-Bové, and Esther Rodríguez-Gallego, and Mayte Blay, and Montserrat Pinent, and Anna Ardévol, and Ximena Terra, and Raúl Beltrán-Debón
January 2015, Molecular medicine reports,
Copied contents to your clipboard!